Cardiac Diagnostics: The Horse is Out of the Barn

The cardiac diagnostic marker field, dormant for years, is changing so rapiidly that studies done five years ago are out of date. Current markers are inreasingly significant in guiding treatment and a lot of promising new markers are in development. As new markers attract the interest of researchers and clinicians, their adoption is likely to be influenced by the history of troponins for detecting MI and the up-and-coming marker for heart failure, BNP. That's the message of E. Magnus Ohman, MD, chief of the division of cardiology at UNC, who spoke at the AACC's annual meeting in July.

The cardiac marker field, dormant for years, is changing so rapidly that studies done five years ago are completely out of date. Interest in the field is keen for good reason: current markers are increasingly significant in guiding treatment and a lot of promising new markers are in development. Within five to ten years, the kinds of markers used to categorize heart disease will change significantly. And tests we don't yet know of today will almost certainly have a role in determining when to give specific therapies.

That's the message from E. Magnus Ohman, MD, chief of the division of cardiology at the University of North Carolina (UNC) Heart Center and an expert on cardiac markers. He...

More from Clinical Trials

More from R&D